Vol. 4, Issue 10, Part E (2018)

Abstract
Enhanced therapeutics is drug products derived from existing drugs that provide additional benefits to the patients and the healthcare system. Now a day’s pulmonary drug delivery gaining substantial interest as an alternative route for administration of systematically acting drugs that are poorly absorbed from the gastrointestinal tract or are pre systemically metabolized molecules. Generally half of all pharmaceuticals are not soluble in water, but are soluble in lipid. As the lung is able to absorb both water and oil into the tissue, solubility is not a constraint for pulmonary delivery. The inhalation route is a fast and effective way of delivering medication locally to the lungs and also for the systemic administration of certain agents. Inhalation therapy has been employed as the mainstay of the treatment in chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The progress of dry powder inhaler (DPI) technology has created opportunities in other therapeutic areas where systemic exposure is required. Low dosed drugs and large molecules have been successfully delivered via the respiratory tract for the treatment of systemic diseases. The formulation and the container closure systems collectively constitute the drug product. Drug contain in pressurized metered dose inhalers (PMDIS) is suspended or dissolve in a volatile propellant, which is atomized for breath-coordinated inhalation.